18 November 2016 – Exco InTouch, the leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, today announced that it has been recognized in Deloitte’s 2016 UK Fast 50 technology awards – securing the award in acknowledgment of the rapid growth achieved by the company over the course of the last four years. The accolade recognizes the success of Exco InTouch as the market leader in its field and pioneer of key innovations that have transformed the sector.
Central to the company’s growth strategy has been its commitment to improving lives for patients through utilizing technological advances to continuously enhance patient engagement, data capture and digital health solutions. Exco InTouch established the use of digital and mobile technology in clinical trials, including patient engagement services, eCOA (electronic Clinical Outcome Assessments) and ePRO (electronic Patient Reported Outcomes) capture.
The recent launch of the company’s Gather™ product suite – simplifying the clinical trial process for patients, investigative sites and pharmaceutical companies – is one of the key developments that Exco InTouch has brought to the field of mobile healthcare. Furthermore, its patented mDNA® technology, an automated management tool that seamlessly identifies, distributes and manages patients and their mobile device interactivity, enables the secure use of BYOD (bring your own device) approaches in both clinical research and healthcare programs.
Exco InTouch’s turnover is forecast to continue to grow significantly over the course of the next 12 months. Over 180 highly skilled personnel, with advanced expertise in mobile and digital technology, are employed across its international sites.
Tim Davis, CEO and Founder of Exco InTouch, commented: “We are delighted to have secured this accolade in recognition of the fact that we have emerged as one of the top 50 fastest growing technology companies in the UK. As the leader in our field, we look forward to continuing to drive technological innovation for both clinical trial and digital health programs. We will continue to bring the benefits of our robust and groundbreaking offerings to the benefit of patients and all key stakeholders to further improve health outcomes.”
He added: “The scope for sustained high growth for our company moving forwards is strong. This is as a result of the continued rapid expansion of the technological solutions market within the clinical and healthcare sectors and our firmly established partnerships with pharma companies in both the US and Europe.”